Strategic Partnerships Avero Diagnostics recently expanded through a notable affiliation with Versant Diagnostics, signaling openness to physician services partnerships and potential cross-selling of specialized pathology services to Versant’s network.

Subspecialty Expansion The firm maintains a strong focus on subspecialized pathology areas such as breast, dermatopathology, gynecologic, GI, molecular, and urologic pathology, presenting clear opportunities to upsell tiered pathology testing and molecular assays to hospitals and clinics seeking deeper diagnostic precision.

AMBLor Advantage With AMBLor for early-stage melanoma risk assessment launched and ongoing development licensed from AMLo Biosciences, there is a sellable differentiated test portfolio that can be offered to oncology and dermatology accounts seeking innovative, early detection capabilities.

Women's Health Growth Recent product expansions in women's health including BD SurePath and Onclarity HPV assays indicate readiness to engage obstetrics-gynecology and cancer screening programs, suggesting target opportunities with women’s health networks and hospital systems expanding screening services.

Tech-Driven Service The tech stack leveraging AWS, Salesforce, Jira, and analytics indicates scalable service delivery and CRM capabilities to support enterprise accounts, enabling targeted outreach, case management, and data-driven proposals for large hospital systems seeking integrated pathology workflows.